HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation.

Abstract
Metabolic syndrome (MetS) is a complex medical disorder characterized by insulin resistance, hypertension, and high risk of coronary disease and stroke. Microvascular rarefaction and endothelial dysfunction have also been linked with MetS, and recent evidence from clinical studies supports the efficacy of incretin-based antidiabetic therapies for vascular protection in diabetes. Previous studies pointed out the importance of dipeptidyl peptidase-4 (DPP-4) inhibition in endothelial cells due to getting protection against metabolic pathologies. We therefore aimed to investigate the acute effects of a DPP-4 inhibitor, sitagliptin, on vascular function in rats with high-sucrose diet-induced MetS. In order to elucidate the mechanisms implicated in the effects of DPP-4 inhibition, we tested the involvement of NO pathway and epigenetic regulation in the MetS. Acute use of sitagliptin protects the vascular function in the rats with MetS in part due to NO pathway via restoring the depressed aortic relaxation responses mediated by receptors. Application of sitagliptin enhanced the depressed phosphorylation levels of both the endothelial NO synthase and the apoptotic status of protein kinase B, known as Akt, in endothelium-intact thoracic aorta from rats with MetS. One-hour application of sitagliptin on aortic rings from rats with MetS also induced remarkable histon posttranslational modifications such as increased expression of H3K27Me3, but not of H3K27Me2, resulting in an accumulation of the H3K27Me3. Our findings suggest that, in addition to its well-known hypoglycemic action, sitagliptin may also have beneficial effects on hyperglycemia-induced vascular changes in an endotheium-dependent manner. These present results with sitagliptin aside from the glycaemic control, may demonstrate its important role in the treatment of patients with MetS.
AuthorsFigen Amber Cicek, Cicek Figen Amber, Zeynep Tokcaer-Keskin, Tokcaer-Keskin Zeynep, Evren Ozcinar, Ozcinar Evren, Yosuf Bozkus, Bozkus Yusuf, Kamil Can Akcali, Akcali Kamil Can, Belma Turan, Turan Belma
JournalMolecular biology reports (Mol Biol Rep) Vol. 41 Issue 8 Pg. 4853-63 (Aug 2014) ISSN: 1573-4978 [Electronic] Netherlands
PMID24838371 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dipeptidyl-Peptidase IV Inhibitors
  • Histones
  • Pyrazines
  • Triazoles
  • Sucrose
  • Sitagliptin Phosphate
Topics
  • Analysis of Variance
  • Animals
  • Aorta (drug effects, pathology)
  • Blotting, Western
  • Dipeptidyl-Peptidase IV Inhibitors (pharmacology)
  • Epigenesis, Genetic (drug effects)
  • Fluorescent Antibody Technique
  • Histones (drug effects)
  • Metabolic Syndrome (chemically induced, drug therapy)
  • Pyrazines (pharmacology)
  • Rats
  • Sitagliptin Phosphate
  • Sucrose (administration & dosage, adverse effects)
  • Triazoles (pharmacology)
  • Vasodilation (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: